<?xml version="1.0" encoding="UTF-8"?>
<p>Chlorpromazine, a drug not yet used in the treatment of coronaviruses despite experimental results (
 <xref rid="B110" ref-type="bibr">Yang and Shen, 2020</xref>) is able to inhibit clathrin-dependent endocytosis. Baricitinib, an anti-Janus kinase inhibitor used as an anti-inflammatory drug in rheumatoid arthritis could regulate clarthrin-mediated endoctytosis and inhibit the release of cytokines (
 <xref rid="B80" ref-type="bibr">Richardson et al., 2020</xref>; 
 <xref rid="B91" ref-type="bibr">Stebbing et al., 2020</xref>). In this respect, baricitinib entered in May a phase 3 of a clinical trial on the treatment of symptomatic COVID-19 in combination with either Lopinavir/Ritonavir (NCT04320277) or remdesivir (NCT04401579). Also, ruxolitinib, another anti-Janus kinase inhibitor is an immunomodulator currently approved by the FDA for treatment of polycythemia vera is currently studied in a Phase 3 clinical trial in patients with COVID-19â€“associated cytokine storm (NCT04362137, RUXOVID). Despite the anti-inflammatory effect (
 <xref rid="B113" ref-type="bibr">Yeleswaram et al., 2020</xref>), the side effects and safety profile of ruloxitinib are still unclear (
 <xref rid="B34" ref-type="bibr">Gaspari et al., 2020</xref>).
</p>
